191 related articles for article (PubMed ID: 32758151)
1. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
[TBL] [Abstract][Full Text] [Related]
2. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
[TBL] [Abstract][Full Text] [Related]
3. A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease.
Mathew JF; Panackel C; Jacob M; Ramesh G; John N
J Clin Exp Hepatol; 2024; 14(5):101407. PubMed ID: 38699513
[TBL] [Abstract][Full Text] [Related]
4. Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease.
Behari J; Bradley A; Townsend K; Becich MJ; Cappella N; Chuang CH; Fernandez SA; Ford DE; Kirchner HL; Morgan R; Paranjape A; Silverstein JC; Williams DA; Donahoo WT; Asrani SK; Ntanios F; Ateya M; Hegeman-Dingle R; McLeod E; McTigue K
Dig Dis Sci; 2024 Feb; 69(2):370-383. PubMed ID: 38060170
[TBL] [Abstract][Full Text] [Related]
5. Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An Observational Study.
Sharma D; Anand G; Meena S; Bhardwaj V
Obes Surg; 2024 Apr; 34(4):1247-1256. PubMed ID: 38411879
[TBL] [Abstract][Full Text] [Related]
6. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
7. Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.
Moore JA; Wheless WH; Zhang J; Marsden J; Mauldin PD; Moran WP; Schreiner AD
Dig Dis Sci; 2023 Jul; 68(7):2946-2953. PubMed ID: 37193930
[TBL] [Abstract][Full Text] [Related]
8. Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis.
Zhang W; Zhang J; Shi H; Liu F; Yu H; Shi H
Hepatol Int; 2023 Oct; 17(5):1170-1181. PubMed ID: 37278869
[TBL] [Abstract][Full Text] [Related]
9. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
Taru MG; Tefas C; Neamti L; Minciuna I; Taru V; Maniu A; Rusu I; Petrushev B; Procopciuc LM; Leucuta DC; Procopet B; Ferri S; Lupsor-Platon M; Stefanescu H
PLoS One; 2024; 19(5):e0303971. PubMed ID: 38781158
[TBL] [Abstract][Full Text] [Related]
10. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
[TBL] [Abstract][Full Text] [Related]
11. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease.
Li G; Lin H; Sripongpun P; Liang LY; Zhang X; Wong VWS; Wong GLH; Kim WR; Yip TCF
Liver Int; 2024 Jan; 44(1):15-26. PubMed ID: 37650363
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.
Sanyal AJ; Shankar SS; Yates KP; Bolognese J; Daly E; Dehn CA; Neuschwander-Tetri B; Kowdley K; Vuppalanchi R; Behling C; Tonascia J; Samir A; Sirlin C; Sherlock SP; Fowler K; Heymann H; Kamphaus TN; Loomba R; Calle RA
Nat Med; 2023 Oct; 29(10):2656-2664. PubMed ID: 37679433
[TBL] [Abstract][Full Text] [Related]
14. Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients.
Franck M; John K; Al Aoua S; Rau M; Geier A; Schattenberg JM; Wedemeyer H; Schulze-Osthoff K; Bantel H
Liver Int; 2023 Dec; 43(12):2668-2679. PubMed ID: 37534777
[TBL] [Abstract][Full Text] [Related]
15. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
[TBL] [Abstract][Full Text] [Related]
16. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency.
Luger M; Kruschitz R; Kienbacher C; Traussnigg S; Langer FB; Schindler K; Würger T; Wrba F; Trauner M; Prager G; Ludvik B
Obes Surg; 2016 Oct; 26(10):2425-32. PubMed ID: 26989059
[TBL] [Abstract][Full Text] [Related]
18. Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening.
de Souza Echeverria L; Mounzer DLS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 Feb; 34(2):389-395. PubMed ID: 38110785
[TBL] [Abstract][Full Text] [Related]
19. Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery.
Raverdy V; Tavaglione F; Chatelain E; Caiazzo R; Saponaro C; Lassailly G; Verkindt H; Baud G; Marciniak C; Chetboun M; Oukhouya-Daoud N; Gnemmi V; Leteurtre E; Duhamel A; Philippe M; Marot G; Romeo S; Pattou F
Metabolism; 2024 Apr; 153():155790. PubMed ID: 38219973
[TBL] [Abstract][Full Text] [Related]
20. Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH).
Mounika N; Yadav A; Kamboj P; Banerjee SK; Deka UJ; Kaur S; Adela R
PLoS One; 2023; 18(12):e0295839. PubMed ID: 38127951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
